Evidence map›Paper›PMID 30859124›Full record

ArticleInternational journal of cardiology. Heart & vasculature2019

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension.

M C J van Thor, L Ten Klooster, R J Snijder, M C Post, J J Mager

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Does combination therapy work in chronic thromboembolic pulmonary hypertension?International journal of cardiology. Heart & vasculature · 2020
    Article
  9. Safety and efficacy of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension in the Netherlands.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M C J van ThorDept of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
L Ten KloosterDept of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.
R J SnijderDept of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.
M C PostDept of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
J J MagerDept of Pulmonology, St. Antonius Hospital, Nieuwegein, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo improve clinical outcome, patients with inoperable and residual chronic thromboembolic pulmonary hypertension (CTEPH) can be treated with riociguat. The aim of this study is to explore long-term outcomes and to compare our 'real world' data with previous research.

methodsWe included all consecutive patients with technical inoperable and residual CTEPH, in whom riociguat therapy was initiated from January 2014 onwards, with patients followed till January 2019. Survival, clinical worsening (CW), functional class (FC), N-terminal pro brain natriuretic peptide (NT-proBNP) and 6-minute walking distance (6MWD) were described yearly after riociguat initiation.

resultsThirty-six patients (50% female, mean age 64.9 ± 12.1 years, 54% WHO FC III/IV and 6MWD 337 ± 138 m could be included, with a mean follow-up of 2.3 ± 1.2 years. Survival and CW-free survival three years after initiation of riociguat were 94% and 78%, respectively. The 6MWD per 10 m at baseline was a significant predictor (HR 0.90 [0.83-0.97],

conclusionOur study confirms that riociguat is an effective treatment in patients with technical inoperable and residual CTEPH at long-term follow-up. Although our results are consistent with previous studies, more 'real world' research is necessary to confirm long-term results.

Indexed as

6MWD, 6-minute walking distanceAE, adverse eventBPA, balloon pulmonary angioplastyCHEST, Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator TrialChronic thromboembolic pulmonary hypertensionClinical outcomeClinical worseningCO, cardiac outputCTEPH, chronic thromboembolic pulmonary hypertensionCW, clinical worseninge.g., exempli gratiāERA, endothelin receptor antagonistFC, functional classHR, hazards regressioni.e., id estmPAP, mean pulmonary arterial pressureNT-proBNP, N-terminal pro brain natriuretic peptidePAH, pulmonary arterial hypertensionPAP, pulmonary arterial pressurePEA, pulmonary endarterectomyPH, pulmonary hypertensionPVR, pulmonary vascular resistanceRAP, right atrial pressureResidual PH, persistent pulmonary hypertension after PEARiociguatSD, standard deviationsGC, soluble guanylate cyclaseSurvivalWHO, World Health Organization

Identifiers

PMID30859124
PMCPMC6396196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.